Protocol Ledger

NCT03941093 · Phase III · COMPLETED

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Panc

Interventional Phase III clinical trial protocol NCT03941093 sponsored by Kyntra Bio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-10 Enrollment: 284 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03941093
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)284 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03941093
Protocol FieldVerified Registry Value
NCT IdentifierNCT03941093
Consolidated Lead SponsorKyntra Bio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment284 participants (ACTUAL)
Registered Start Date2019-05-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI